AKESO's Class 1 new drug Inunisumab Injection approved for listing
I'm PortAI, I can summarize articles.
Kangfang Biotech's Class 1 new drug Inclisiran Injection (AK102) has been approved for listing by the National Medical Products Administration (NMPA) of China. This drug is suitable for adult patients with primary hypercholesterolemia and mixed dyslipidemia who, despite treatment with statins on top of dietary control, still cannot achieve the target low-density lipoprotein cholesterol (LDL-C) levels. Inclisiran works by binding to PCSK9, blocking its interaction with LDL-R, and enhancing the clearance ability of LDL-C
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments